By Joey Wong, Director of Investor Research, Hong Kong BD, LSN
Many large corporations establish ventures or innovation arms to invest in and partner with life science and healthcare startups. Unlike traditional institutional VCs, corporate venture capital (CVC) groups bring unique strategies, goals, and ties to their parent organizations. Some CVCs focus closely on opportunities that align with the corporation’s core businesses, while others pursue innovation beyond existing portfolios, creating broader avenues for collaboration.
This 50-minute discussion will bring together leaders from corporate venture arms of global pharma, biotech, medtech, and healthcare corporations. Panelists will share how they evaluate early-stage opportunities, what distinguishes their investment criteria from institutional VCs, and how they balance strategic alignment with financial return. Startups will also gain valuable perspective on how to approach CVCs, what additional benefits they can expect beyond funding, and how relationships and collaboration may evolve post-investment.
For entrepreneurs seeking strategic partners, this session offers a chance to hear directly from active CVC investors about how they drive innovation, accelerate R&D, and bring transformative solutions to the market.
 Andrew Merken Shareholder Polsinelli PC (Moderator) |
 Komeil Nasrollahi Sr. Director Innovation & Venture Partnerships Siemens Healthineers |
 Claire Leurent Managing Director AbbVie Ventures |
 Jeffrey Moore President MP Healthcare Venture Management (MPH) |
 Alex de Winter VP of New Ventures Danaher Corporation |
Join us at RESI Boston this September to take part in this discussion and connect with investors across the life science and healthcare ecosystem.
Next Phase Newsletter 
Leave a comment